Choosing kinase and pathway antibodies: what a pdgfr alpha antibody, an fgfr4 antibody, a btk antibody, an mtor antibody and a yap1 antibody each report, why the phospho reagent and the total reagent answer different questions, and the inhibitor control that proves the band

Pathway antibodies are bought in pairs and used as if they were one reagent. A total antibody reports how much kinase is present, which moves over hours; a phospho reagent reports activity at a residue, which moves in seconds and is lost in the lysis buffer if inhibitors were not already there. This page covers the pairs, the handling and the one control that settles a doubtful band.

the ratio a pathway result is read as
phospho / total
the specificity control that proves a phospho band
an inhibitor
the authentication guidance a funded study is expected to follow
NIH rigor

Figures in this panel are the validation and labelling rules a research antibody is bought and used under, named from the guidance itself and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a reagent price index it has not measured.

Running a pathway experiment

  1. Buy the pair and read the ratio. Phospho signal is read against total protein on the same samples, because the informative quantity is the fraction activated. Normalising a phospho band to a loading control alone cannot separate more activation from more kinase.
  2. Put phosphatase inhibitors in before you lyse. Dephosphorylation begins the moment a cell breaks. Inhibitors go into the buffer fresh, the plate goes on ice and the lysate is handled cold and fast. Most missing phospho signal is lost in the first minute and no optimisation recovers it.
  3. Use a selective inhibitor as the specificity control. A band that disappears when the kinase is inhibited is the kinase's band. This is the strongest and cheapest specificity evidence available for a phospho reagent and it is routinely skipped in favour of an isotype control that proves much less.
  4. Check the residue and its conservation. Phospho antibodies are residue specific and different sites report different downstream consequences. Put the residue in the methods, and confirm the surrounding sequence is conserved in your species before assuming cross-reactivity.
  5. Remember that some of these move rather than change. A transcriptional co-activator is regulated by shuttling between cytoplasm and nucleus, so a whole-cell blot can be flat while the biology changes entirely. For those targets, fractionate or measure a per-cell nuclear ratio by imaging.

Time courses, because pathways are transient

Receptor and downstream phosphorylation peak within minutes and decay, so a single time point sits somewhere on a curve you have not measured. A short course is what makes a comparison between conditions mean anything.

When comparing cell lines, the kinetics themselves usually differ, so matching one time point across lines compares the timing rather than the magnitude of the response.

Alternatives to the blot

Immunoassay formats quantify phosphorylation across many samples reproducibly, and cytometry measures it per cell, which reveals whether a population responds uniformly or a subset responds strongly. Both answer questions a blot averages away.

For a screen, a plate-based phospho immunoassay is far more practical than a blot per condition and is what makes a dose response across many compounds feasible.

Common questions

Why is my phospho band missing?
Handling, almost always. Phosphatase inhibitors must be in the lysis buffer before lysis, and everything kept cold and fast. A stimulated positive control tells you in one lane whether it is handling or biology.
What is the best specificity control for a phospho antibody?
A selective inhibitor of the kinase. A band that disappears under inhibition is the kinase's band, which is far stronger evidence than an isotype control and usually cheaper than a genetic approach.
Should phospho be normalised to total or to a loading control?
To total on the same samples. The meaningful quantity is the fraction of the protein that is phosphorylated, and a loading control alone conflates activation with abundance.
Why is my co-activator blot flat when the treatment clearly works?
Because it is regulated by moving rather than by amount. Fractionate into nuclear and cytoplasmic pools, or image and measure a nuclear to cytoplasmic ratio per cell.

Get a shortlist for your project

Free. We send a shortlist of vendors whose published prices and service scope fit what you described, built from the verified index on this site. We may email you about this enquiry and similar services from this site; opt out any time, including from the first message.

Browse by service class

Sources

Cite or embed this figure

The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.

Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/kinase-pathway-antibodies/.

Embed this figure (plain HTML, no scripts)
median advertised gene synthesis price per base pair · the US research synthesis services market · August 2026

$0.11

Middle 50%$0.07 – $0.15
verified vendor service pages4

Source: BioBricks Synthesis Price Index

Get a vendor shortlistCompare synthesis prices